Roxane, Ranbaxy Launch Biaxin Generics
This article was originally published in The Pink Sheet Daily
Executive Summary
Clarithromycin immediate-release generics enter the market following expiration of Abbott’s compound patent; litigation over other patents is ongoing.
You may also be interested in...
Teva's Biaxin XL Generic Would Irreparably Harm Abbott, Court Rules
Teva is preliminarily enjoined from launching extended-release clarithromycin pending a ruling on the merits of patent infringement claims. A Chicago federal judge preliminarily rules that only one of three Abbott patents at issue is valid. Teva expects to file an expedited appeal to the Federal Circuit.
Teva's Biaxin XL Generic Would Irreparably Harm Abbott, Court Rules
Teva is preliminarily enjoined from launching extended-release clarithromycin pending a ruling on the merits of patent infringement claims. A Chicago federal judge preliminarily rules that only one of three Abbott patents at issue is valid. Teva expects to file an expedited appeal to the Federal Circuit.
Teva’s Biaxin XL Generic Barred From Launch Pending May 26 Hearing
A temporary restraining order prevents Teva from launching its extended-release generic upon the May 23 expiration of the clarithromycin compound patent. Abbott already has gotten a jump on potential generic versions of immediate-release Biaxin with an “authorized” generic sold through Dava.